Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000685654 | SCV000813142 | likely benign | Long QT syndrome | 2022-11-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003303108 | SCV004005091 | likely benign | Cardiovascular phenotype | 2023-06-05 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003411592 | SCV004112734 | uncertain significance | CACNA1C-related disorder | 2023-03-16 | criteria provided, single submitter | clinical testing | The CACNA1C c.447A>G variant is not predicted to result in an amino acid change (p.=). This variant may introduce a cryptic splice site based on splicing prediction programs (Alamut Visual Plus v.1.6.1). However, these prediction programs are not equivalent to functional evidence. To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant has been interpreted as likely benign by a single submitter in ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/variation/565959/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |